Scientific Opinion on the re-evaluation of canthaxanthin (E 161 g) as a food additive

EFSA Journal

Volumn 8, Issue 10, 2010, Pages

[No Author Info available]

Author keywords

4,4 dioxo carotene; 4 dione; Canthaxanthin; CAS 514 78 3; Colour Index 40850; E 161g; EINECS 208 187 2; carotene 4

Indexed keywords

EID: 85078376666     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2010.1852     Document Type: Article

References (113)

1. AFSSA (Agence française de sécurité des aliments), 2009. Report of the 2006/2007 individual and national study on food consumption 2 (INCA2., coordinator L.Lafay). www.afssa.fr
2. Allen BC, Kavlock RJ, Kimmel CA and Faustman EM, 1994. Dose-response assessment for developmental toxicity. II. Comparison of generic Benchmark dose estimates with No Observed Adverse Effects Levels. Fundamental and Applied Toxicology 23, 487–495.
3. Arden GB and Barker FM, 1991. Canthaxanthin and the eye: A critical ocular toxicologic assessment. Journal of Toxicology-Cutaneous and Ocular Toxicology 10, 115–155.
4. Arden GB, Oluwole JO, Polkinghorne P, Bird AC, Barker FM, Norris PG and Hawk JL, 1989. Monitoring of patients taking canthaxanthin and carotene: an electroretinographic and ophthalmological survey. Human and Experimental Toxicology 8, 439–450.
5. Astorg P, Gradelet S, Leclerc J, Canivenc MC and Siess MH, 1994. Effects of B-carotene and canthaxanthin on liver xenobiotic-metabolizing enzymes in the rat. Food and Chemical Toxicology 32 (8), 735–742.
6. Barker FM, Arden GB, Bird AC, Hawk JLM and Norris PG, 1987. The ERG in canthaxanthin therapy. Poster presented at meeting of the Association of Research in Vision and Ophthalmology, Sarasota, Florida, May 4–8, 1987.
7. Barker FM and Fox JG, 1992. The ferret ERG in high dosage canthaxanthin administration. Unpublished research report submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland. (as referred to by JECFA, 1995)
8. Bausch J, 1992a. (14C)-Canthaxanthin: Absorption, Distribution and Excretion Following Oral Administration at Steady State in the Cynomolgus Monkey. Unpublished research report No. 106 798, submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland. (as referred to by JECFA, 1995 and SCF, 1997)
9. Bausch J, 1992b. Canthaxanthin Metabolic Studies: Comparison of Rat Results with Monkey Results. Unpublished research report No. B-106 799, submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland. (as referred to by JECFA, 1995 and SCF, 1997)
10. Bendich A and Shapiro SS, 1986. Effect of β-Carotene and canthaxanthin on the immune responses of the rat. Journal of Nutrition 116, 2254–2262.
11. Bluhm R, Branch R, Johnston P and Stein R, 1990. Aplastic-anemia associated with canthaxanthin ingested for tanning purposes. JAMA 264, 1141–1142.
12. Bokkers BGH and Slob W, 2007. Deriving a data-based interspecies assessment factor using the NOAEL and the Benchmark dose approach. Critical Reviews in Toxicology 37, 353–377.
13. Boudreault G, Cortin P, Corriveau LA, Rousseau AP, Tardif Y, and Malenfant M, 1983. La réinopathie à la canthaxanthine: 1. Etude clinique de 51 consommateurs. Canadian Journal of Ophtalmology 18, 325–328.
14. Brown ED, Blakely SR, Babu U, Grundel E and Mitchell GV, 1997. Vegetable concentrates interact with canthaxanthin to affect carotenoid bioavailability and superoxide dismutase activity but not immune response in rats. Nutrition Research 17, 989–998.
15. Bruinink A, Cohn W and Weiser H, 1992. Chick embryonic neuronal retina, RPE, brain and meninges cell cultures as a model for canthaxanthin induced alterations in the eye. Unpublished research report submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland (as referred to by JECFA, 1995 and SCF, 1997).
16. Buser S, 1987a. Canthaxanthin potential tumourigenic and toxic effects in prolonged dietary administration to mice. Unpublished Report No. HLR135/861058 of Huntingdon Research Centre Ltd. Submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland.
17. Buser S, 1987b. Canthaxanthin in a three-generation study in rats. Unpublished Report No. HLR 138/86755 of Huntingdon Research Centre Ltd. Submitted by F. Hoffmann-La Roche & Co., Basel, Switzerland.
18. Buser S, 1992a. Canthaxanthin (Ro 01–9915) in a long-term study with male rats (feed admixture). Unpublished research report B-157′342, submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland (as referred to by JECFA, 1995 and SCF, 1997).
19. Buser S, 1992b. Canthaxanthin (Ro 01–9915) in a long-term study with female rats (feed admixture). Unpublished research report B-157′343 submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland (as referred to by JECFA, 1995 and SCF, 1997).
20. Buser S and Banken L, 1988. Canthaxanthin (Ro 01–9915) in a combined tumourigenicity/toxicity study in rats. Histopathological re-evaluation and statistical analysis. Unpublished Research Report No. B-119′973 submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
21. Buser S, Goralczyk R, Bausch J and Schüep W, 1993. Canthaxanthin (Ro 01–9915) in a long-term study with Cynomolgus monkeys (oral gavage); 3-year interim report. Unpublished research report no. B-161′152 submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland (as referred to by JECFA, 1995).
22. Buser S, Goralczyk R, Bausch J and Schüep W, 1994. Canthaxanthin (RO 01- 9915) in a long-term study with Cynomolgus monkeys (oral gavage); 3-year final report. Unpublished research report no. B-161′152 submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland (as referred to by JECFA, 1995).
23. Buser S and Hummler H, 1980. Tolerance study with Ro 01–9915 (Canthaxanthene) beadlets, 10% water soluble) administered orally as a food admixture to dogs over 13 weeks. Unpublished report.
24. CIAA (Confederation of the Food and Drink Industries of the EU). Exercise on occurrence data - EFSA re-evaluation of some food colours. December 2009.
25. CEFIC, 2007. Food Regulatory Panel represented by sa.qual Regulatory Affairs Services GmbH. Canthaxanthin (E 161 g) – Re-evaluation of food colours: call for data – Parma, 7 December 2006. Data submitted on behalf of two FRP-members on 30 March 2007.
26. CEN/TC 275, 2007. Foodstuffs – Determination of Astaxanthin and canthaxanthin in fish flesh. Technical report, working document, 1–15Chan W and McCance RA, 1995. Meat poultry and game: fifth supplement to the fifth edition of McCance and Widdowson's. The composition of foods. Royal Society of Chemistry and Ministry of Agriculture, Fisheries and Food: Cambridge.
27. ChemIDplus advanced (via internet, 2008). Accessible via: chem.sis.nlm.nih.gov/chemidplus
28. Chesterman H, Fox PA, Heywood R, Street AE and Prentice DE, 1979. Canthanaxanthin preliminary toxicity study in beagle dogs. Unpublished Report No. HLR76/79686 of Huntingdon Research Centre submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
29. Chételat A, 1981. Mutagenicity evaluation of Ro 01–9915 (Canthaxanthin) in the Ames Salmonella/mammalian microsome plate test. Unpublished Report No. B-95 575 submitted to WHO by F. Hoffmann La-Roche & Co., Basle, Switzerland.
30. Chételat A, 1986. Mutagenicity evaluation of Ro 01–9915 (Canthaxanthin) with Saccharomyces cerevisiae D7. Unpublished Research Report No. B-105′448 submitted to WHO by F. Hoffmann-La Roche, & Co., Basle, Switzerland.
31. Chew BP and Park JS, 2004. Carotenoid action on the immune response. Journal of Nutrition 134, 257S–261S.
32. Chan W and McCance RA, 1995. Meat Poultry and Game: Fifth Supplement to the Fifth Edition of McCance and Widdowson's. The composition of foods. Royal Society of Chemistry and Ministry of Agriculture, Fisheries and Food, Cambridge, 1995.
33. Choubert G and Luquet P, 1979. Influence de l'agglomération et du stockage des aliments composés sur leur teneur en canthaxanthine: Conséuences sur la digestibilité et la fixation de ce pigment chez la truite arc-en-ciel. Annual Zootechnology 28, 145–157. (as referred to by SCAN, 2002)
34. Clark RM, Yao L, She L and Furr HC, 1998. A comparison of lycopene and canthaxanthin absorption: using the rat to study the absorption of non-provitamin A carotenoids. Lipids 33(2), 159–163.
35. Clark RM and Furr HC, 2001. Absorption of Canthaxanthin by the rat is influenced by total lipid in the intestinal lumen. Lipids 36, 473–5.
36. Cohn W and Schalch W, 1990. The biokinetic properties of canthaxanthin. Unpublished Research Report No. B-156′905. F. Hoffmann-La Roche & Co., Basle, Switzerland.
37. Cortin P, Corriveau LA, Rousseau AP, Tardif Y, Malenfant M and Boudreault G, 1982. Maculopathy with golden granules. Canadian Journal of Ophthalmology 17, 103–106.
38. Cortin P, Boudreault, G, Rousseau AP, Tardif Y and Malenfant M, 1984. La rétinoépathien à la Canthaxanthine: 2. Facteurs prédisposants. Canadian Journal of Ophtalmology 19, 215–219.
39. Eckhardt K, 1982. Embrytoxicity study in rabbits with oral administration of Ro 01–9915. Canthaxanthin. Segment II teratological study. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
40. EFSA (European Food Safety Authority), 2007. Opinion of the Scientific Panel on Additives and Products or Substances used in Animal Feed on the Maximum Residue Limits for canthaxanthin in foodstuffs coming from animals fed with canthaxanthin used as a feed additive in accordance with Council Directive 70/524/EEC. Adopted on 14 June 2007. The EFSA Journal 507, 1–19.
41. EFSA (European Food Safety Authority), 2009. Use of the benchmark dose approach in risk assessment1 Guidance of the Scientific Committee. The EFSA Journal 1150, 1–72.
42. nd Edition, 35–38.
43. Ernst H, 2002. Recent advances in industrial carotenoid synthesis. Pure and Applied Chemistry 74, 2213–2226.
44. FDA (U.S. Food and Drug Administration), 2005. Tanning pills. Available at: www.fda.gov/cosmetics/productandingredientsafety/productinformation/ucm134217.htm
45. FDA (U.S. Food and Drug Administration), 2009. CFR - Code of Federal Regulations Title 21. Part 73 - Listing of color additives exempt from certification. Available at: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=73.75.
46. Fowles JR, Alexeeff GV and Dodge D, 1999. The use of benchmark dose methodology with acute inhalation lethality data. Regulatory Toxicology and Pharmacology 29, 262–278.
47. Fox JG, Taylor NS and Blanco M, 1992. Is the Ferret a Model to Study Canthaxanthin Retinopathy? Report submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland. (as referred to by JECFA, 1995)
48. Gallandre F, 1980. Mutagenicity studies with canthaxanthin in mammalian systems. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
49. Glaser T, Lienau A, Zeeb D, Krucker M, Dachtler M and Albert K, 2003. Qualitative and quantitative determination of carotenoid stereoisomers in a variety of spinach samples by use of MSPD before HPLC-UV, HPLC-APCI-MS, and HPLC-NMR on-line coupling. Chromatographia (Supplement), 57, 19–25.
50. Glatzle D and Bausch J, 1988a. Canthaxanthin balance studies - first results. Research report No. B-106′707. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
51. Glatzle D and Bausch J, 1988b. Accumulation and depletion of canthaxanthin and astaxanthin in kidney fat of rats. Research report No. B-106′690. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
52. Glatzle D and Bausch J, 1989. Canthaxanthin Balance Studies. Unpublished research report No. B-106 714 submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland (as referred to by JECFA, 1995).
53. Goralczyk R and Weiser H, 1992. Birefringent particles in eyes of chicks after a very high dietary intake of canthaxanthin. Unpublished research report B-158′278 submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland (as referred to by JECFA, 1995)-
54. Goralczyk R, Bausch J and Weiser H, 1993a. Dose-dependent occurrence of canthaxanthin-related birefringent particles in the retina of broiler chicks. Unpublished research report No. B-158′295 submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland.
55. Goralczyk R, 1993b. Post mortem examination of ferret eye tissue after long term feeding of canthaxanthin. Unpublished research report No. B-158′296 submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland.
56. Goralczyk R, Buser S, Bausch J, Bee W, Zilhlke U and Barker FM, 1997. Occurrence of Birefringent Retinal Inclusions in Cynomolgus Monkeys After High Doses of canthaxanthin. Investigative Ophthalmology and Visual Sciences 38, 741–752.
57. Goralczyk R, Barker FM, Buser S, Liechti H and Bausch J, 2000. Dose Dependency of Canthaxanthin Crystals in Monkey Retina and Spatial Distribution of its Metabolites. Investigative Ophthalmology and Visual Sciences 41, 1513–1522.
58. Harling RJ, Burford P, Heywood R, Street AE, Chanter DO, Read R and Gopintah C, 1987. Canthaxanthin toxicity to dogs by repeated dietary administration for 52 weeks. Unpublished Report No. HLR137/85682 of Huntingdon Research Centre Ltd., submitted to WHO by F. Hoffmann-La & Roche & Co., Basle, Switzerland.
59. Hoffmann-La Roche, 1966. Canthaxanthin. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland (as referred to by JECFA, 1990. Available from: www.inchem.org/documents/jecfa/jecmono/v26je06.htm).
60. Hoffmann-La Roche, 1986. Canthaxanthin. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland (as referred to by JECFA, 1990. Available from: www.inchem.org/documents/jecfa/jecmono/v26je06.htm).
61. th, 1991
62. Holland B, Unwin ID, Buss DH, McCance RA and Widdowson EM, 1989. McCance and Widdowson's the composition of foods. 4th supplement, Milk products and eggs, 4th ed. Royal Society of Chemistry and Ministry of Agriculture, Fisheries and Food: London: HMSO.
63. IUNA (Irish Universities Nutrition Alliance), 2001. North/South Ireland Food Consumption Survey, 1997–1999 www.iuna.net/index.php/research/northsouth-food-survey
64. IUNA (Irish Universities Nutrition Alliance), 2005. National Children's Food Survey, 2004. www.iuna.net/childrens_survey/
65. JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1974. Eighteenth report of the Joint FAO/WHO Expert Committee on Food Additives. Evaluation of certain food additives. World Health Organization. Technical Report Series, No 557.
66. JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1987. Thirty-first report of the Joint FAO/WHO Expert Committee on Food Additives. Evaluation of certain food additives and contaminants. World Health Organization. Technical Report Series, No 759. Available from: whqlibdoc.who.int/trs/WHO_TRS_759.pdf
67. JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1988. Toxicological evaluation of certain food additives. World Health Organization. Food Additives Series, No 22, nos 635 on INCHEM. Available from: www.inchem.org/documents/jecfa/jecmono/v22je09.htm
68. JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1990. Toxicological evaluation of certain food additives and contaminants. World Health Organization. Food Additives Series, No 26, nos 685 on INCHEM. Available from: www.inchem.org/documents/jecfa/jecmono/v26je06.htm
69. JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1995. Forty-fourth report of the Joint FAO/WHO Expert Committee on Food Additives. Evaluation of certain food additives and contaminants. World Health Organization. Technical Report Series, No 859. Available from: whqlibdoc.who.int/trs/WHO_TRS_859.pdf
70. JECFA (Joint FAO/WHO Expert Committee on Food Additives), 1996. Toxicological evaluation of certain food additives and contaminants. World Health Organization. Food Additives Series, No 35, nos 839 on INCHEM. Available from: www.inchem.org/documents/jecfa/jecmono/v35je08.htm
71. JECFA (Joint FAO/WHO Expert Committee on Food Additives), 2008. Combined Compendium of Food Additive Specifications. Monograph 5. Canthaxanthin. Available from: www.fao.org/ag/agn/jecfa-additives/specs/monograph5/additive-101-m5.pdf
72. th report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series 952, 66.
73. Juhlin L, 1981. Recurrent urticaria: clinical investigation of 330 patients. British Journal of Dermatology 104, 369–381.
74. Kistler A, 1982. Embryotoxicity study in rats with oral administration (feed admix) of Ro 01–9915, Canthaxanthin. Phase II - teratological study with postnatal evaluation. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
75. Kläui H and Bauernfeind JC, 1981. Carotenoids as Food Color. In: Carotenoids as Colorants and Vitamin A Precursors. Eds Stewart GF, Hawthorn J and Schweigert BS. Elsevier Science. ISBN: 0120828502
76. Köpcke W, Barker FM and Schalch W, 1995. Canthaxanthin-deposition in the retina. A biostatistical evaluation of 411 cases taking this carotenoid for medical or cosmetical purposes. Journal of Toxicology-Cutaneous and Ocular Toxicology 14, 89–104.
77. Kubler W, 1986. Biokinetic evaluation of canthaxanthin plasma levels after multiple doses of 1 mg and 8 mg Canthaxanthin. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
78. Minguez-Mosquera MI, Hornero-Mendez D and Garrido-Fernandez, 1995. Detection of Bixin, Lycopene, canthaxanthin and β-Apo-8′-Carotenal in Products derived from Red Pepper. Journal of AOAC International 78(2), 491–496.
79. Norris PG and Hawk JLM, 1987. Significance of retinal crystals in patients treated with photoprotective carotenoids. Retinoids Today and Tomorrow 8, 27–28.
80. Norris PG and Hawk JLM, 1990. A study of hepatic function during carotenoid therapy for erythropoietic protoporphyria. Unpublished report submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland (as referred to by JECFA, 1995 and SCF, 1997).
81. Oosterhuis JA, Nijman NM, de Wolff FA and Remky H, 1988. Canthaxanthin retinopathy with and without intake of canthaxanthin as a drug. Human and Toxicology Abstracts 7, 45–47.
82. Paetau I, Chen HP, Goh NMY and White WS, 1997. Interactions in the postprandial appearance of β-carotene and canthaxanthin in plasma triacylglycerol-rich lipoproteins in humans. American Journal of Clinical Nutrition 66, 1133–1143.
83. Prabhala RH, Maxey V, Hicks MJ and Watson RR, 1989. Enhancement of the expression of activation markers of human peripheral blood mononuclear cells by in vitro culture with retinoids and carotenoids. Journal of Leukocyte Biology 45, 249–254.
84. Ros AM, Leyon H and Wennersten G, 1985. Crystalline retinopathy in patients taking an oral drug containing canthaxanthin. Photodermatology 2, 183–185.
85. Rose PH, Crook D, Gopinath C, Gibson WA and Majeed SK, 1988. Canthaxanthin potential tumorigenic and toxic effects in prolonged dietary administration to rats. Unpublished Report No. HLR134/86980 of the Huntingdon Research Centre Ltd. Submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
86. Rubaj J, Bielecka G, Korol W and Kwiatek K, 2009. Determination of canthaxanthin in premixture and compound feed by the liquid chromatography method. Bulletin of the Veterinary Institute in Pulawy 53, 707–712
87. Scallon LJ, Mieler WF, Kies JC, Aaberg TM and Burke JM, 1987. Canthaxanthin retinopathy: an animal model. Investigative Ophthalmology and Visual Sciences 28, 9.
88. Scallon LJ, Burke JM, Mieler WF, Kies JC and Aberg TM, 1988. Cantaxanthine-induced retinal pigment epithelial changes in the cat. Current Eye Research 7, 687–693.
89. Schalch W, 1988. Biokinetic evaluation of canthaxanthin in humans. Unpublished Research Report No. B-107′134 submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
90. Schalch, 1990. Canthaxanthin retinopathy in monkeys: clinical and histopathological studies. Unpublished research report submitted to WHO by F. Hoffman-La Roche & Co., Basel, Switzerland.
91. Schieber A and Carle R, 2005. Occurrence of carotenoid cis-isomers in food: Technological, analytical, and nutritional implications. Trends in Food Science and Technology 16, 416–422.
92. Schiedt K, Bischof S and Glinz E, 1992. Analysis of carotenoids and retinoids in eye tissues of various species after canthaxanthin long-term treatment. Unpublished research report no. B-157′006 submitted to WHO by F. Hoffmann-La Roche & Co., Basel, Switzerland.
93. Schierle J and Frey C, 2007a. Determination of Apoester and Canthaxanthin in Poultry Tissue. Paper submitted to EFSA by DSM Nutritional Products Ltd, 1–4.
94. Schierle J and Frey C, 2007b. Determination of Apoester and Canthaxanthin in Egg Yolk. Paper submitted to EFSA by DSM Nutritional Products Ltd, 1–4.
95. SCAN (Scientific Committee on Animal Nutrition), 2002. Opinion of the Scientific Committee on Animal Nutrition on the use of canthaxanthin in feedingstuffs for salmon and trout, laying hens, and other poultry, opinion expressed 2002, 1–29.
96. th series, Cat. N$dG EUR 8752), Colouring Matters authorized for use in Foodstuffs intended for Human Consumption (Opinion expressed on 7 July 1983, 48. Available from: ec.europa.eu/food/fs/sc/scf/reports/scf_reports_14.pdf
97. st series, (Cat. N$dG EUR 11617), opinion expressed 1987, 1–18. Available from: ec.europa.eu/food/fs/sc/scf/reports/scf_reports_21.pdf
98. rd series, ISBN 92-828-5887-1). Opinion on canthaxanthin (Expressed on 13th June 1997) 1997, 28–33. Available from: ec.europa.eu/food/fs/sc/scf/reports/scf_reports_43.pdf
99. Schwartz JL, Flynn E and Shklar G, 1990. The effect of carotenoids on the antitumor immune response in vivo and in vitro with hamster and mouse effectors. Micronutr. Immunol. Function 587, 92–109.
100. Scotter MJ and Castle L, 2004. Chemical interactions between additives in foodstuffs: a review. Food Additives and Contaminants 21(2), 93–124.
101. Shih CK, Chang JH, Yang SH, Chou TW and Cheng HH, 2008. β-Carotene and canthaxanthin alter the pro-oxidation and antioxidation balance in rats fed a high-cholesterol and high-fat diet. British Journal of Nutrition 99 (1), 59–66.
102. Steiger A and Hummler H, 1981. Tolerance study with Ro 01–9915 (Canthaxanthene, beadlets 10% water soluble) administered orally to mice over 13 weeks. Unpublished Report No. RCR B-87 284 submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
103. Steiger A and Buser S, 1982. Tolerance study with Ro 01–9915 (Canthaxanthene, beadlets 10% water soluble) administered orally as food admixture to rats over 13 weeks. Unpublished Report No. B-87 283 submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
104. Strobel R, 1986. Gene mutation assay in mammalian cells with dry canthaxanthin Type 10 CWS, Ro 01-9915/063 (V79/HGPRT Test). Unpublished Research Report No. B-153′076 submitted to WHO by F. Hoffmann-La Roche & Co., Basle, Switzerland.
105. Sujak A, 2009. Interactions between canthaxanthin and lipid membranes - possible mechanisms of canthaxanthin toxicity. Cellular and Molecular Biology Letters 14, 395–410.
106. Tang G, Dolnikowski GG, Blanco MC, Fox JG and Russell RM, 1993. Serum carotenoids and retinoids in ferrets fed canthaxanthin. Journal of Nutritional Biochemistry 4, 58–63.
107. Tang G, Blanco MC, Fox JG and Russell RM, 1995. Supplementing ferrets with canthaxanthin affects the tissue distributions of canthaxanthin, ether carotenoids, vitamin-A and vitamin-E. Journal of Nutrition 125, 1945–1951.
108. TemaNord, 2002. Food additives in Europe 2000; Status of safety assessments of food additives presently permitted in the EU. TemaNord 2002, 560, 191–194.
109. van Het HK, West CE, Weststrate JA and Hautvast JGAJ (2000). Dietary Factors that affect the bioavailability of carotenoids. Journal of Nutrition 130, 503–506.
110. Weber U, Goerz G, Kern W and Michaelis L, 1987a. Clinical and experimental findings in carotenoid retinopathy. Concepts in Toxicology 4, 105–109.
111. Weber U, Kern W, Novotny GEK, Goerz G and Hanappel S, 1987b. Experimental carotenoid retinopathy. l. Functional and morphological alterations of the rabbit retina after 11 months dietary application. Graefe's Archives for Clinical and Experimental Ophthalmology 225, 198–205.
112. White WS, Peck KM, Bieber TL, Gugger ET and Erdman JW Jr, 1993. Interactions of oral β-carotene and canthaxanthin in ferrets. Journal of Nutrition 123, 1405–1413.
113. White WS, Stacewicz-Saputantzakis M, Erdman JW Jr, and Bowen PE, 1994. Pharmacokinetics of beta-carotene and canthaxanthin after ingestion of individual and combined doses by human-subjects. Journal of of the American College of Nutrition 13, 665–671.